scholarly journals Correlation between fasting blood glucose, postprandial blood glucose and glycated hemoglobin in non-insulin treated type 2 diabetic subjects

2013 ◽  
Vol 1 (1) ◽  
pp. 18-21 ◽  
Author(s):  
L Shrestha ◽  
B Jha ◽  
B Yadav ◽  
S Sharma
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Glycated Hemoglobin ◽  
Fasting Blood Glucose ◽  
University Teaching ◽  
Postprandial Blood Glucose ◽  
Diabetic Patients ◽  
Type 2 Diabetic ◽  
Better Than

Background: Diabetes mellitus (DM) comprises a group of common metabolic disorders that share phenotype of hyperglycemia. Objectives: This study was conducted to determine the correlation between glucose monitoring by fasting blood glucose or two hours postprandial blood glucose with glycated hemoglobin (HbA1c) in type 2 diabetic patients. Method: A cross sectional study was conducted over a period of six month in the Department of Biochemistry. Institute of Medical, Tribhuvan University Teaching Hospital. Sixty inpatients with Diabetes mellitus type 2 were assessed for daily fasting and postprandial blood sugar for 15 consecutive days. HbA1c was measured on the 15th day. Result: Both postprandial blood glucose and fasting blood glucose significantly correlated with HbA1c. Postprandial blood glucose showed better correlation to HbA1c than fasting blood glucose (r = 0.630, P <0.001 vs. r =0.452, P = 0.05). Conclusion: These results show that postprandial blood glucose correlated better than fasting blood glucose to HbA1c. Thus, postprandial blood glucose predicted overall glycemic control better than fasting blood glucose. This finding has potential implications for treatment and monitoring of metabolic control in type-2 diabetes. DOI: http://dx.doi.org/10.3126/stcj.v1i1.8654 Sunsari Technical College Journal Vol.1(1) 2012 18-21

scholarly journals STUDY OF RELATIONSHIP BETWEEN THE PROTEIN OXIDATION MARKERS AND ADIPOKINES IN OBESE TYPE 2 DIABETIC PATIENTS

2019 ◽  
pp. 204-209 ◽  
Author(s):  
SUKHPAL SINGH ◽  
AMITA MAHAJAN ◽  
JASPREET KAUR
Keyword(s):  
Blood Glucose ◽  
Protein Oxidation ◽  
Fasting Blood Glucose ◽  
Protein Carbonyl ◽  
Postprandial Blood Glucose ◽  
Diabetic Patients ◽  
Model Assessment ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Objective: This study was done to explore the correlation if any, between obesity markers adiponectin, leptin, and protein oxidative stress (OS) status in obese with and without type 2 diabetic mellitus (T2DM) patients. Methods: In the present study, 30 healthy subjects, 30 obese non-diabetics, and 30 obese T2DM patients were enrolled. Protein OS parameters such as advanced oxidation of protein products (AOPPs) and protein carbonyl (PC) were estimated. Serum leptin, adiponectin, and insulin levels were measured by ELISA. Results: The AOPP, PC, leptin, leptin adiponectin ratio (LAR), insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) levels were significantly higher in obese non-diabetic and obese T2DM as compared to healthy control (p<0.001). However, serum adiponectin levels were significantly lower in obese non-diabetic and obese T2DM as compared to control (p<0.001). HOMA-IR and LAR both the index of IR were increased in obese non-diabetic and obese T2DM. Positive correlations were observed for AOPP with body mass index, PC in obese non-diabetic and with fasting blood glucose, postprandial blood glucose, HOMA-IR, and PC in obese T2DM. A negative correlation was found between PC and adiponectin in obese non-diabetic and obese T2DM. A significant inverse correlation was obtained between leptin and adiponectin in obese T2DM only. Conclusion: The present study suggested that increased protein OS, hyperinsulinemia, and hyperleptinemia may lead to hypoadiponectinemia in obese with and without T2DM. Moreover, determination of protein oxidation markers can be useful for monitoring the dysregulation of adipokines and glucose metabolism in obesity and T2DM.

scholarly journals Study on the prevalence of dyslipidemia in type 2 diabetes mellitus

2019 ◽  
Vol 6 (3) ◽  
pp. 786
Author(s):  
Eda Dayakar ◽  
C. Sathya Sree ◽  
E. Sanjay
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Diabetic

Background: Diabetes mellitus is a common health problem globally. Dyslipidaemia is a major risk factor to develop cardiovascular disease in diabetics. They present study was undertaken to find out the prevalence of dyslipidaemia in type 2 diabetic patients.Methods: The present study was a cross sectional study consisting of 46 (23 male and 23 female) known type 2 diabetes mellitus patients. Age, gender, duration of diabetes, body mass index (BMI) was recorder in all the diabetic patients.  Fasting blood glucose levels, total cholesterol, triglycerides, HDL, LDL, VLDL levels were measured using standard methods and recorded.Results: The average total cholesterol, triglycerides, LDL, HDL and VLDL were 200±42mg/dl, 169.62±89.79mg/dl, 132.45±36.38mg/dl,39.1±16.6mg/dl and 35.85±17.09mg/dl respectively. The incidence of occurrence of hypercholesterolemia was 58.6% and hypertriglyceridemia 36.9%. Increased levels of LDL were observed in 30 (65.2%) patients and reduced HDL was observed in 43 (93.4%) patients. The incidence rate of dyslipidaemia was higher in female diabetic patients when compared to male diabetic patients.Conclusions: Awareness on the dyslipidaemia and its risk factors should be provided to the type 2 diabetic patients as they are more prone to get cardiovascular disease and lipid profile also should be monitored regularly along with blood glucose levels.

scholarly journals Alterations of liver enzymes in T2DM: a case control study

2018 ◽  
Vol 5 (6) ◽  
pp. 1521
Author(s):  
Chandrashekhar G. S.
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Case Control Study ◽  
Liver Enzymes ◽  
Fasting Blood Glucose ◽  
Case Control ◽  
Diabetic Patients ◽  
Histopathological Analysis ◽  
Control Study

Background: Liver plays an important role in regulation of blood glucose in fed state as well as in fasting. Diabetes mellitus can result as a consequence of liver disorder and vice versa. Objective of the present study is to compare the liver enzymes in type 2 diabetic patients as compared to non-diabetic patients.Methods: A case- control study was conducted in Clinical Biochemistry Laboratory, Adarsha Super speciality Hospital, Udupi from April 2018 to August 2018. The data of 174 diabetic patients and 118 healthy people as controls was collected. Fasting blood glucose, aspartate aminotransferase (AST), alanine amino transferase (ALT) and alkaline phosphatase (ALP) were estimated in the study subjects.Results: It was found that AST levels (47.55±4.69U/L) in diabetics extremely significantly high as compared to controls (33.51±2.33U/L). ALT levels were insignificantly high in diabetics compared to controls. ALP was significantly elevated (p=0.0002) in diabetics. Correlation study showed a weak positive correlation between AST, ALT and blood glucose. Odds ratio showed a higher risk of liver enzyme elevation in diabetics. Risk of elevation of AST was found to be 1.65 times high and ALT was 1.25 times high in diabetics compared to non-diabetics.Conclusions: Diabetics had high liver enzymes as compared to non-diabetics. An association was found between type 2 diabetes mellitus and liver enzymes. For better characterization of cause and effect, further studies need to be done on alterations in liver function tests along with the histopathological analysis of liver biopsy samples.

scholarly journals Influence of Patient Characteristics on The Type of Insulin Therapy Obtained by Diabetes Type 2 Outpatient in Denpasar Municipality

2017 ◽  
Vol 1 (2) ◽  
pp. 139
Author(s):  
Luh Putu Febrayana Larasanty ◽  
I GNA. Dewantara Putra ◽  
Rhyce Dewata Sari ◽  
Komang Dede Saputra ◽  
I GA. Gede Minanjaya ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Insulin Therapy ◽  
Glucose Level ◽  
Medical Records ◽  
Fasting Blood Glucose ◽  
Patient Characteristics ◽  
Postprandial Blood Glucose

This study aims to investigate the influence of patient characteristics on the choice of insulin therapy in type 2 diabetes mellitus outpatients in Denpasar municipality. This is a descriptive analysis study using the patient's medical records as research material. Patients who meet inclusion and exclusion criteria are being recorded based on their medical records. Characteristics that are taken are age, gender, fasting blood glucose level (FBG), 2-hour postprandial blood glucose level (2-hours PPG) and HbA1c values of patients. Types of insulin therapy gained from patient medical records and drug use report in pharmacy. Characteristics data and type of insulin analyzed using correlation test to determine the effect of the patient characteristics on the selection of insulin therapy. 43 patients became the research subject. Males gendered patients (72.09%) and the patients aged less than 65 years (90.70%) are the dominant characteristics of the research subjects. The average value of FBG of patients is 212 mg / dL; 2-hours PPG 280 mg / dL and HbA1c 10.1%. There is a correlation between sex, age, HbA1c value and FBG with the type of insulin obtained by patients (p <0.05). Based on the results of statistical tests, age and gender have a strong correlation on insulin choice, HbA1c and FBG level has a moderate influence and 2-hours PPG have a weak correlation. Patient characteristics had an influence on the type of insulin choice for diabetes mellitus type 2 outpatient in the Denpasar municipality.

scholarly journals The Application of Plasma 1,5-Anhydro-D-glucitol for Monitoring Type 2 Diabetic Patients

2005 ◽  
Vol 21 (3) ◽  
pp. 127-132 ◽  
Author(s):  
Marzena Dworacka ◽  
Hanna Winiarska
Keyword(s):  
Blood Glucose ◽  
Plasma Level ◽  
Multivariate Regression Analysis ◽  
Postprandial Blood Glucose ◽  
Effective Control ◽  
Diabetic Patients ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Aim: Recent data have suggested that effective control of postprandial blood glucose can reduce the risk of macroangiopathic complications of diabetes, especially cardiovascular risk. 1,5-Anhydro-D-glucitol (1,5-AG) has been proposed as a marker of short-term hyperglycaemic excursions. We aimed to evaluate its usefulness in patients with type 2 diabetes and have attempted to indicate when 1,5-AG monitoring should be used in ordinary diabetes care settings. Methods: The study group consisted of 130 type 2 diabetic patients aged 36–69 years. 1,5-AG plasma level, HbA1c concentrations and daily glucose profile were measured. Mean blood glucose (MBG), M-value were calculated and maximal daily glycaemia (MxG) was established as indicators of short-term hyperglycaemic episodes. Results: 1,5-AG plasma level was negatively and HbA1c was positively correlated with fasting glycaemia (FG), MBG, M-value and MxG. Multivariate regression analysis revealed that 1,5-AG plasma level is determined by MxG only, while FG determined HbA1c concentration in blood. The analysis of 1,5-AG level and HbA1c distributions in well and poorly controlled patients revealed that persons with low HbA1c values may have decreased 1,5-AG plasma level. Conclusion: 1,5-AG plasma level monitoring is the useful method to identify well controlled, exclusively based on HbA1c levels type 2 diabetic patients with transient hyperglycaemia, accordingly patients at high risk of macroangiopathic complications.

Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients

Drug Research ◽  
2018 ◽  
Vol 68 (12) ◽  
pp. 669-672
Author(s):  
Masataka Kusunoki ◽  
Yukie Natsume ◽  
Tetsuro Miyata ◽  
Kazuhiko Tsutsumi ◽  
Yoshiharu Oshida
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Hemoglobin A1c ◽  
Blood Glucose Control ◽  
Sglt2 Inhibitor ◽  
Serum Triglyceride ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

AbstractIn patients with type 2 diabetes mellitus who show suboptimal blood glucose control under insulin therapy alone, concomitant treatment with an additional hypoglycemic agent that differs in its mechanism of action from insulin may be considered. We conducted this clinical trial to explore whether further control of increased blood glucose level can be achieved with concomitant use of sodium glucose co-transporter 2 (SGLT2) inhibitor as concomitant with other hypoglycemic therapy, as compared to SGLT2 inhibitor monotherapy, in patients with type 2 diabetes mellitus showing decrease in blood glucose level but less than the effect of insulin monotherapy and there was no significant differences. In the SGLT2 inhibitor monotherapy group, decreases of the serum hemoglobin A1c (HbA1c) level, body weight, body mass index (BMI) and serum triglyceride, and elevation of the serum high density lipoprotein cholesterol concentration were observed as compared to the baseline values. In the type 2 diabetic patients under insulin therapy who received combined insulin plus SGLT2 inhibitor therapy, however decreases in the body weight and BMI, with only a tendency towards decrease of the serum HbA1c value, not reaching statistical significance, were observed. The combined therapy group also showed no appreciable changes of the serum triglyceride level, while the serum adiponectin level increased. The present study data indicate that combined insulin plus SGLT2 inhibitor treatment failed to afford any further improvement of the blood glucose control, as compared to SGLT2 monotherapy, in Japanese type 2 diabetic patients.

scholarly journals Comparison of Different Clinical and Metabolic Parameters Among Type 2 Diabetic Patients With and Without Retinopathy in Primary Health Clinics in Medan City, North Sumatera, Indonesia

2020 ◽  
Vol 31 (2) ◽  
pp. 64-68
Author(s):  
Rusdiana ◽  
Sry Suryani Widjaja ◽  
Mila Hayati Daulay ◽  
Almaycano Ginting
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Blood Glucose ◽  
Lipid Profile ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Primary Health ◽  
Significant Difference ◽  
Type 2 Diabetic

Background: The global prevalence of type 2 diabetes mellitus is increasing steadily and diabeticretinopathy is one of the microvascular complications of diabetes mellitus. This research aims tocompare different clinical and metabolic parameters among type 2 diabetic patients with and withoutdiabetic retinopathy. Methods: This cross-sectional study was done at various primary health care centers in Medan cityand the surrounding areas in North Sumatera from May to July 2020. Collected medical data includedblood pressure, body mass index, duration of disease, family history and medical treatment. Laboratorydata included blood glucose, glycated hemoglobin (HbA1c) and lipid profile. Diabetic retinopathy wasdetected by funduscopic examination by an ophthalmologist. Results: Total patients were 88 and 26 had retinopathy. There was significant difference betweenthe average blood pressure, blood glucose and HbA1C values among patients with type 2 diabetesmellitus with and without retinopathy (p<0.005). But, there was no significant difference between theaverage body mass index (BMI), abdominal circumference and lipid profile. Conclusion: Study showed that type 2 diabetic patients with retinopathy had increased blood glucoselevels and HbA1c than patients without retinopathy. Bangladesh J Medicine July 2020; 31(2) :64-68

scholarly journals Efficacy and safety of bromocriptine quick release as an add on therapy with metformin and glipizide in type 2 diabetes mellitus patients: an open label randomized controlled study

2019 ◽  
Vol 8 (4) ◽  
pp. 669
Author(s):  
Nithyapriya M. ◽  
S. Purushotaman
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Control Group ◽  
Study Group ◽  
Quick Release ◽  
Type 2 Dm

Background: Type 2 Diabetes Mellitus (DM) is a metabolic disorder, treated by insulin and oral hypoglycaemic agents (OHA). Despite treatment, to protect diabetic population from its complications is difficult. So, there is a need for an OHA with different mechanism of action and minimal side effects. Bromocriptine Mesylate QR (Quick release) formulation was approved by FDA for treatment of type 2 DM. Hence, this study was planned to highlight the usefulness of Bromocriptine QR in type 2 diabetes mellitus.Methods: Total 140 patients with type 2 DM were randomized into two groups. The control group was treated with Metformin 500 mg BD (twice daily) and Glipizide 5 mg BD for a period of 3 months. The study group received Bromocriptine quick release 1.6 mg once daily, metformin 500 mg BD and Glipizide 5 mg BD for a period of 3 months. In both control and study groups, fasting blood glucose, postprandial blood glucose was monitored at 0, 1st, 2nd and 3rd month. HbA1C was done at baseline and at the end of 3 months.Results: There was statistically significant decrease in fasting blood glucose, postprandial blood glucose and HbA1C when compared to baseline in both control group (p <0.05) and study group (p <0.05) at the end of 3 months. But the decrease in FBS, PPBS, HbA1C was higher in the study group (p=0.0001) than the control group (p=0.001).Conclusions: In type 2 DM patients, Bromocriptine QR, combined with metformin and Glipizide reduced fasting and postprandial blood glucose and HbA1C significantly compared to metformin and glipizide alone.

Sign in / Sign up

Export Citation Format

Share Document